Effects of Omega-3 Fatty Acid Supplementation on Vascular Access Thrombosis in Polytetrafluorethylene Grafts

Bowden, Rodney G.; Wilson, Ronald L.; Gentile, Mindy; Ounpraseuth, Songthip; Moore, Page C.; Leutholtz, Brian

doi:10.1053/j.jrn.2006.07.009

Cited by 22 publications

(31 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table summarizes RCT that have investigated the effect of ω3FA supplementation on hemodialysis access failure. Three RCT have assessed their effect on AVG patency . The largest study showed a notable but nonsignificant reduction in the proportion of participants experiencing either AVG thrombosis or radiological or surgical intervention during 12 months of follow‐up (48% in participants randomized to daily ω3FA compared to 62% in participants randomized to placebo, P = .06).…”

Section: Clinical Trials Of Omega‐3 Polyunsaturated Fatty Acid Supplementioning

confidence: 99%

The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled

Viecelli

Mori

Roy‐Chaudhury³

et al. 2017

Seminars in Dialysis

View full text Add to dashboard Cite

In patients receiving hemodialysis, the provision of safe and effective vascular access using an arteriovenous fistula or graft is regarded as a critical priority by patients and health professionals. Vascular access failure is associated with morbidity and mortality, such that strategies to prevent these outcomes are essential. Inadequate vascular remodeling and neointimal hyperplasia resulting in stenosis and frequently thrombosis are critical to the pathogenesis of access failure. Systemic medical therapies with pleiotropic effects including antiplatelet agents, omega-3 polyunsaturated fatty acids (fish oils), statins, and inhibitors of the renin-angiotensin-aldosterone system (RAAS) may reduce vascular access failure by promoting vascular access maturation and reducing stenosis and thrombosis through antiproliferative, antiaggregatory, anti-inflammatory and vasodilatory effects. Despite such promise, the results of retrospective analyses and randomized controlled trials of these agents on arteriovenous fistula and graft outcomes have been mixed. This review describes the current understanding of the pathogenesis of arteriovenous fistula and graft failure, the biological effects of antiplatelet agents, fish oil supplementation, RAAS blockers and statins that may be beneficial in improving vascular access survival, results from clinical trials that have investigated the effect of these agents on arteriovenous fistula and graft outcomes, and it explores future therapeutic approaches combining these agents with novel treatment strategies.

show abstract

Section: Clinical Trials Of Omega‐3 Polyunsaturated Fatty Acid Supplementioning

confidence: 99%

The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled

Viecelli

Mori

Roy‐Chaudhury³

et al. 2017

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

“…While this trial was small with limited generalizability 16 , it provided an important basis for our study. A second study randomized 29 patients with new forearm loop grafts to over-the-counter omega-3 fatty acids (0.96 g EPA/day and 0.6 g DHA/day) versus placebo and did not observe any difference in 8 month AV-graft patency 39 . In addition to the small sample size, the lower doses of EPA and DHA might have contributed to lack of effect.…”

Section: Commentsmentioning

confidence: 99%

Effect of Fish Oil Supplementation on Graft Patency and Cardiovascular Events Among Patients With New Synthetic Arteriovenous Hemodialysis Grafts

Lok

Moist

Hemmelgarn

et al. 2012

JAMA

126

148

View full text Add to dashboard Cite

“…128,129 Findings from these studies suggest that n-3 PUFAs have antithrombotic, antiproliferative and anti-aggregatory platelet effects. 130 These FAs can influence gene regulation by down-regulating gene expression of platelet-derived growth factors and suppress the platelet activating factor, a potent platelet aggregator and leukocyte activator.…”

Section: Pufas and Haematological Parametersmentioning

confidence: 99%

Polyunsaturated fatty acids in health and disease

et al. 2013

View full text Add to dashboard Cite

Polyunsaturated fatty acids (PUFAs) are necessary for overall health. The two PUFAs families, n-6 and n-3 fatty acid are physiologically and metabolically distinct. Proportion of PUFAs in serum and erythrocyte phospholipids is an important determinant of both health and disease, and depends on endogenous metabolism controlled by genetic polymorphisms and dietary intake. Both n-3 and n-6 PUFAs are processed to powerful promoters of eicosanoids synthesis at the cyclooxygenase and lipoxygenase level. Evidence from observational and intervention studies suggest that n-3 PUFAs are cardioprotective, perhaps through their anti-inflammatory, anti-arrhythmic, lipid-lowering, and antihypertensive effects. In contrast, dietary n-6 PUFAs have pro-inflammatory effect. Low n-3 and elevated n-6 PUFAs levels were found in patients with cancer on different sites. The present review will focus on the current knowledge related to PUFAs intake and status in health and disease, with reference to the Serbian population. [Projekat Ministarstva nauke Republike Srbije, br. III41030

show abstract

Effects of Omega-3 Fatty Acid Supplementation on Vascular Access Thrombosis in Polytetrafluorethylene Grafts

Cited by 22 publications

References 20 publications

The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled

The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled

Effect of Fish Oil Supplementation on Graft Patency and Cardiovascular Events Among Patients With New Synthetic Arteriovenous Hemodialysis Grafts

Polyunsaturated fatty acids in health and disease

Contact Info

Product

Resources

About